Paradigm Biocapital Advisors LP OCUL — OCULAR THERAPEUTIX INC

Ownership history in Paradigm Biocapital Advisors LP  ·  4 quarters on record

AI Ownership Summary

Paradigm Biocapital Advisors LP reported OCULAR THERAPEUTIX INC (OCUL) in 4 quarterly 13F filings from 2025 Q1 through 2025 Q4. Peak portfolio weight reached 1.36% in 2025 Q2. The latest visible filing shows OCUL at 0.91% of the fund.

This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings.

What this OCUL ownership page tells you

This page is designed to answer the real investor question behind a 13F filing: how meaningful was Paradigm Biocapital Advisors LP's position in OCULAR THERAPEUTIX INC, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.

Freshest filing
Latest Reported Filing
2025 Q4

OCUL was reported at 0.91% of portfolio in the most recent visible filing.

High-water mark
Peak Conviction
1.36% in 2025 Q2

Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.

Time in book
Holding Window
2025 Q1 to 2025 Q4

Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.

Decision context
Why It Matters
Position size beats headlines

Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.

OCUL stock page Paradigm Biocapital Advisors LP fund profile Paradigm Biocapital Advisors LP full holdings
How Paradigm Biocapital Advisors LP held OCUL — position size vs. price
% of Fund (quarterly)    OCUL price (quarter-end, indexed to 100)    SPY (indexed to 100)    QQQ (indexed to 100)
📋 Quarterly Holdings History 4 quarters  ▾
Quarter Action Sold % After 3M Timing Shares Change Chg % % of Fund Mkt Value Filed Price (Filed)
2025 Q4 REDUCED 16.1% -30.2% ✅ 2,935,284 -562,023 -16.1% 0.91% $35.6M 2026-02-17 $6.99
2025 Q3 ADDED — — — 3,497,307 +76,967 +2.3% 1.16% $40.9M 2025-11-14 $11.30
2025 Q2 ADDED — — — 3,420,340 +2,106,322 +160.3% 1.36% $31.7M 2025-08-14 $12.65
2025 Q1 INITIATED — — — 1,314,018 — — 0.44% $9.6M 2025-05-15 $7.17

🏢 Other funds also holding OCUL

As of 2026 Q1 — sorted by position size

SUMMER ROAD LLC 3Y 7Y 70.84% DELTEC ASSET MANAGEMENT LLC 3Y 7Y 3.64% ACUTA CAPITAL PARTNERS, LLC 3Y 7Y 3.54% Venrock Adviser, LLC 3Y 3.27% Octagon Capital Advisors LP 3Y 2.97% Knoll Capital Management, LLC 3Y 7Y 2.82% Deep Track Capital, LP 3Y 2.72% Propel Bio Management, LLC 2.03% KVP Capital Advisors, LP 1.9% Defilade Capital Management, L.P. 1.77%

FAQ About Paradigm Biocapital Advisors LP and OCUL

These are the practical questions this page is built to answer before you even open the full history table.

How long has Paradigm Biocapital Advisors LP reported owning OCUL?

Paradigm Biocapital Advisors LP reported OCUL across 4 quarterly 13F filings, from 2025 Q1 through 2025 Q4.

What was the largest reported OCUL position in Paradigm Biocapital Advisors LP's portfolio?

The largest reported portfolio weight for OCUL was 1.36% in 2025 Q2.

What is the latest reported OCUL position on this page?

The most recent filing on this page is 2025 Q4, when Paradigm Biocapital Advisors LP reported 2,935,284 shares, equal to 0.91% of portfolio, with an estimated market value of $35.6M.

What does the chart on this OCUL ownership page compare?

The chart compares Paradigm Biocapital Advisors LP's quarterly OCUL portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.

How well did Paradigm Biocapital Advisors LP time their OCUL position?

Based on 13F filing dates vs. subsequent OCUL price moves, Paradigm Biocapital Advisors LP correctly timed 1 out of 3 reported position changes (33%). The annualised alpha on OCUL relative to SPY over the holding period was -97.3%.

← Back to Paradigm Biocapital Advisors LP Holdings